Nanoparticle formulations consisting of liposomes increase the delivery and effectiveness of drugs that may not otherwise be permeable to biological barriers. These nanoparticles are proven to increase absorption of several drugs classes, including chemotherapeutics. While several formulations have been designed that increase the systemic absorption of several drugs, less have been identified that degrade at specific locations. Such ability would be invaluable in the design of smart nanoparticles that selectively degrade in the target tissues of interest, such as tumors. Liposome formulations are highly composed of phospholipids including glycerophospholipids such as phosphatidylcholine. Glycerophospholipids are degraded in the body by phospholipases, including phospholipase A2 (PLA2). Recent data demonstrates that human prostate cancers have significantly higher levels of secretory phospholipase A2 (sPLA2) activity and expression compared to control tissue. In many cases the expression and activity of sPLA2 is 20-fold higher than paired controls. This application tests the hypothesis that increased expression and activity of sPLA2 in prostate cancers allows for the design of smart liposomes that are selectively degraded in these tumors.
The Specific Aims designed to test this hypothesis are 1) Determine the mechanisms of PLA2-mediated degradation of liposomes in vitro, 2) Design novel nanoparticulate liposomes capable of being selectively degraded by sPLA2, 3) Identify the role of sPLA2 in the mechanism of degradation of liposomes in prostate cancer cells, and 4) Determine the role of sPLA2 in the mechanisms o liposomal degradation, drug release and efficacy in mouse models of prostate cancer.

Public Health Relevance

Studies proposed in this application will identify drug delivery systems that are selectively degraded in prostate tumors. This will be done by creating systems that are degraded by a lipid-metabolizing enzyme whose expression is 20-fold higher in prostate tumors, compared to normal tissues. In essence, this application will make use of this selective enzyme expression to increase drug delivery to prostate tumors.

Agency
National Institute of Health (NIH)
Institute
National Institute of Biomedical Imaging and Bioengineering (NIBIB)
Type
Exploratory/Developmental Grants (R21)
Project #
1R21EB008153-01A1
Application #
7659138
Study Section
Nanotechnology Study Section (NANO)
Program Officer
Henderson, Lori
Project Start
2009-06-01
Project End
2011-05-31
Budget Start
2009-06-01
Budget End
2010-05-31
Support Year
1
Fiscal Year
2009
Total Cost
$185,521
Indirect Cost
Name
University of Georgia
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
004315578
City
Athens
State
GA
Country
United States
Zip Code
30602
Scholpa, Natalie E; Briggs, Sherri B; Wagner, John J et al. (2016) Cyclin-Dependent Kinase Inhibitor 1a (p21) Modulates Response to Cocaine and Motivated Behaviors. J Pharmacol Exp Ther 357:56-65
Kang, Jeong Yeon; Eggert, Mathew; Mouli, Shravanthi et al. (2015) Pharmacokinetics, antitumor and cardioprotective effects of liposome-encapsulated phenylaminoethyl selenide in human prostate cancer rodent models. Pharm Res 32:852-62
Cummings, Brian S; Pati, Sumitra; Sahin, Serap et al. (2015) Differential effects of cocaine exposure on the abundance of phospholipid species in rat brain and blood. Drug Alcohol Depend 152:147-56
Quach, N D; Mock, J N; Scholpa, N E et al. (2014) Role of the phospholipase A2 receptor in liposome drug delivery in prostate cancer cells. Mol Pharm 11:3443-51
Waters, Katrina M; Cummings, Brian S; Shankaran, Harish et al. (2014) ERK oscillation-dependent gene expression patterns and deregulation by stress response. Chem Res Toxicol 27:1496-503
Scholpa, N E; Zhang, X; Kolli, R T et al. (2014) Epigenetic changes in p21 expression in renal cells after exposure to bromate. Toxicol Sci 141:432-40
Quach, Nhat D; Arnold, Robert D; Cummings, Brian S (2014) Secretory phospholipase A2 enzymes as pharmacological targets for treatment of disease. Biochem Pharmacol 90:338-48
Mock, J N; Costyn, L J; Wilding, S L et al. (2013) Evidence for distinct mechanisms of uptake and antitumor activity of secretory phospholipase A2 responsive liposome in prostate cancer. Integr Biol (Camb) 5:172-82
Mock, Jason N; Taliaferro, John P; Lu, Xiao et al. (2012) Haloenol pyranones and morpholinones as antineoplastic agents of prostate cancer. Bioorg Med Chem Lett 22:4854-8
Zhu, Guodong; Alhamhoom, Yahya; Cummings, Brian S et al. (2011) Synthesis of lipids for development of multifunctional lipid-based drug-carriers. Bioorg Med Chem Lett 21:6370-5

Showing the most recent 10 out of 12 publications